Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Cellectis SA (CLLS)
NASDAQ:CLLS
Holding CLLS?
Track your performance easily
Earnings Data
Report Date
May 07, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
―Last Year’s EPS
-$0.15Same Quarter Last Year
Strong Buy
Based on 4 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 04, 2024
|% Change Since: -6.82%
|Next Earnings Date:May 07, 2025
Earnings Call Sentiment|Neutral
The earnings call highlighted significant strategic and financial progress, particularly with the AstraZeneca collaboration and improved cash position. However, challenges such as the de-prioritization of UCART123 and delays in data release were noted. Overall, the sentiment is balanced with a positive outlook on future developments.Company Guidance
During the Cellectis Third Quarter 2024 Earnings Call, the company provided guidance on several key metrics and strategic decisions. Cellectis announced a strategic collaboration with AstraZeneca, initiating three programs in hematological malignancies, solid tumors, and genetic disorders, with significant milestones including $47 million triggered from the collaboration, comprising $25 million upfront and $22 million from development milestones. The company decided to de-prioritize the UCART123 program, focusing resources on the BALLI-01 and NATHALI-01 clinical trials, with a Phase I data set expected in 2025. Cellectis reported a cash position of $264 million as of September 30, 2024, up from $156 million at the end of 2023, and provided a cash runway extension into 2027. The company emphasized a prudent cash management strategy, focusing on advancing its clinical pipeline and manufacturing capabilities, while planning regulatory interactions to support potential Phase II strategies.Strategic Collaboration with AstraZeneca
Research and development activities started for 3 programs under collaboration with AstraZeneca, including allogeneic CAR T for hematological malignancies and solid tumors, and in vivo gene therapy for genetic disorders.
Financial Position Strengthened
$47 million triggered under AstraZeneca agreement, with $25 million upfront and $22 million in development milestones, enhancing financial position.
Increased Cash Position
Cash, cash equivalents, restricted cash, and fixed-term deposits increased to $264 million as of September 30, 2024, up from $156 million at the end of 2023, due to AstraZeneca's second tranche of equity investment and other financial activities.
Positive Progress in Clinical Trials
Recruitment for BALLI-01 (UCART22) in relapsed/refractory B-cell acute lymphoblastic leukemia completed for all remaining slots. Phase I data expected in 2025.
Extended Cash Runway
Cellectis projects cash sufficiency to fund operations into 2027, reflecting prudent cash management and revenue from partnerships.
---
CLLS Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
CLLS Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 04, 2024 | $1.76 | $1.78 | +1.14% |
| Aug 06, 2024 | $2.07 | $2.06 | -0.48% |
| May 28, 2024 | $2.78 | $2.72 | -2.16% |
| Mar 11, 2024 | $2.59 | $2.43 | -6.18% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Cellectis SA (CLLS) report earnings?
Cellectis SA (CLLS) is schdueled to report earning on May 07, 2025, TBA Not Confirmed.
What is Cellectis SA (CLLS) earnings time?
Cellectis SA (CLLS) earnings time is at May 07, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is CLLS EPS forecast?
Currently, no data Available
---